# Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

> **NCT03974113** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Genzyme, a Sanofi Company** · enrollment: 32 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **DRUG:** Fitusiran

## Key facts

- **NCT ID:** NCT03974113
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-28
- **Primary completion:** 2026-08-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03974113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03974113, "Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03974113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*